Navigation Links
Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
Date:10/17/2011

TARRYTOWN, N.Y., Oct. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) (the "Company") announced that it intends to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2016 in a private placement.  The notes will be offered by the initial purchaser only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.  The Company also intends to grant to the initial purchaser a 13-day option to purchase up to an additional $60 million aggregate principal amount of notes on the same terms and conditions.

The Company intends to use a portion of the proceeds of the offering, together with the proceeds from the warrant transactions, to fund the cost of the convertible note hedge transactions in connection with the offering, each as described below.  The Company intends to use the remaining net proceeds for general corporate purposes.

The notes will be general senior unsecured obligations of the Company.  The notes will be convertible, subject to certain conditions, into cash, shares of common stock of the Company, or a combination of cash and stock, at the Company's option.  The notes will mature on October 1, 2016 unless previously repurchased or converted in accordance with their terms prior to such date.  The interest rate, conversion rate, conversion price and other terms of the notes will be determined at the time of the pricing of the offering.

In connection with the offering of the notes, the Company plans to enter into privately negotiated convertible note hedge and warrant transactions with counterparties that may include the initial purchaser and/or its affiliates.  The convertible note hedge transactions will cover, subject to customary anti-dilution adjustments, the number of shares of the Compa
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
6. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data to Be Presented at Upcoming Medical Meetings
9. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
10. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
(Date:8/19/2014)... From this week,s Eos: Long-Term Ecological Research and Network-Level ... track how a wide range of ecosystems was responding ... would be particularly powerful if it coupled multiple decades ... large-scale, long-term experiments and models from dozens of different ... It is the Long-Term Ecological Research (LTER) Network, which ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... A new study published this week in the journal ... mixing of cold, deep waters from below can change sea ... occurs in a huge region of the ocean that takes ... climate patterns, particularly global warming. Using a new measurement ...
... cell found in the trillions in our brain have made ... injury and disease such as stroke. A University of Bristol ... how astrocyte cells respond to neurological trauma. The star-shaped ... glial cell that comprise one of two main categories of ...
... research team from the School of Basic Medical ... Radix Achyranthis Bidentatae can inhibit advanced glycation end ... cortex, and improve learning and memory capabilities in ... on advanced glycation end product accumulation is associated ...
Cached Biology News:Study explains Pacific equatorial cold water region 2Study explains Pacific equatorial cold water region 3Key target responsible for triggering detrimental effects in brain trauma identified 2
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
Request Info...
... Platypus Contact Printing Kit contains choice of Printing Surface ... Gold over Ti adhesion layer, 1 silicon wafer coated ... or 3 plain glass slides), PDMS Stamps (3 PDMS ... squares or 100 um x 10 mm or 200 ...
Biology Products: